Pacira BioSciences, Inc. (PCRX) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Total Revenue Chart for Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (PCRX) revenue for FY2025 was USD 726.4M, a 3.6% change from FY2024. Pacira BioSciences, Inc.'s revenue grew from USD 13.9M in 2008 to USD 726.4M in 2025 (5116.6% over 17 years). Earnings per share moved from USD -2.64 in 2011 to USD 0.34 in 2022. Revenue compound annual growth rate: 5-year CAGR of 11.1%, 10-year CAGR of 11.3%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $1.45B
- Implied Share Price
- $36.34
- Enterprise Value
- $1.14B
- Revenue (TTM)
- $746.16M
- EBITDA
- $123.97M
- Profit Margin
- 1.96%
- Trailing P/E
- 103.83
- Forward P/E
- 6.25
- Price/Book (MRQ)
- 1.46
- Price/Sales (TTM)
- 1.94
- EV/EBITDA
- 9.84
- EV/Revenue
- 1.53
- Dividend Yield
- —
- Book Value
- $16.87
- Free Cash Flow (FY2025)
- $136.66M
- Free Cash Flow Yield
- 9.42%
Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.